Black Diamond Thera

$3.84 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Black Diamond Thera

Black Diamond Therapeutics, Inc. is a precision oncology medicine company. The Company’s technology platform, Mutation-Allostery-Pharmacology (MAP) platform is designed to allow it to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. The Company has designed its lead product candidate, BDTX-189, to block the function of an undrugged family of oncogenic proteins defined by mutations which occur across a range of tumor types, and which affect both the epidermal growth factor receptor (EGFR) and the tyrosine-protein kinase ErbB-2, or HER2.

Stock Analysis

last close $3.97
1-mo return -29.1%
3-mo return -49.7%
avg daily vol. 1.39M
52-week high 29.62
52-week low 3.95
market cap. $154M
forward pe -
annual div. -
roe -44.8%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 85.1%

Subscribe now for daily local and international financial news